KCNIP3 and systemic sclerosis: Our study demonstrates that A20 mRNA therapy effectively suppresses fibrosis by restoring A20 expression, inhibiting TRAF6/NF-κB signaling, and downregulating DREAM in an in vivo model of SSc.